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Abstract We have explored the process of oligomerization of
G protein-coupled purinergic receptors, adenosine A1 receptor
(A1R) and P2Y1 receptor (P2Y1R), in intact HEK293T cells by
means of modi¢ed bioluminescence resonance energy transfer
technology (BRET2) that o¡ers greatly improved separation
of the emission spectra of the donor and acceptor moieties com-
pared to traditional BRET. This approach identi¢ed both con-
stitutive and agonist-promoted heteromeric oligomerization be-
tween Myc-tagged P2Y1R fused to a donor, Renilla luciferase
(Myc-P2Y1R-Rluc) and HA-tagged A1R fused to an acceptor, a
di¡erent form of green £uorescent protein (HA-A1R-GFP2).
The BRET2 signal increased in a time-dependent manner in
the cells expressing HA-A1R-GFP2/Myc-P2Y1R-Rluc upon ad-
dition of agonists for both receptors, which could be inhibited by
pretreatment with the P2Y1R antagonist MRS2179. A high
degree of HA-A1R-GFP2 and Myc-P2Y1R-Rluc co-localization
in the co-transfected HEK293T cells was also observed by con-
focal laser microscopy. These results indicate that A1R and
P2Y1R can form constitutive hetero-oligomers in living cells
and this process is promoted by the simultaneous activation of
both receptors. 4 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Purines such as adenosine or ATP are involved in modulat-
ing many physiological processes, including cardioprotection,
pain, sleep, neurotransmission, and neuromodulation [1].
They exert such diverse biological processes via speci¢c cell
surface receptors termed purinergic receptors which are divid-
ed into two main subfamilies, namely adenosine or P1 recep-
tors and ATP or P2 receptors. The P1 receptors have been
further subdivided into A1, A2A, A2B and A3, all of which are
G protein-coupled receptors (GPCRs). The P2 receptors are
also subclassi¢ed into P2Xð17Þ receptors, which are ligand-
gated ion channels, and P2Yð1;2;4;6;11;12Þ receptors, which are
GPCRs. However, despite extensive studies, details of the
physiological functions of the purinergic receptor subtypes
remain unclear, especially on complex cross-talk interactions
in vivo as described in the rat hippocampal neuron [2] and
also in the rat portal vein [3].
Recently, a signi¢cant number of GPCRs have been shown
to exist in homomeric or heteromeric oligomers [4]. It has
been suggested that this oligomerization represents a general
phenomenon among GPCRs, resulting in a greater diversity
of GPCR signaling. In fact, we recently reported that Gi=o
protein-coupled adenosine A1 receptors (A1Rs) and Gq=11
protein-coupled P2Y receptor, subtype P2Y1Rs form a het-
eromeric complex in HEK293T cells where A1R exerts
P2Y1R-like agonistic e¡ects [5]. We therefore speculated
that this heteromeric assembly between purinergic recep-
tors produces a hybrid pharmacology that explains the hith-
erto unde¢ned physiological functions of purines and an in-
creased diversity of purine signaling in various tissues and
cells.
In the present study, we took advantage of a recently de-
veloped approach, known as BRET (bioluminescence reso-
nance energy transfer) [6], to investigate whether A1R and
P2Y1R could exist as heteromers in living cells. BRET is
strictly dependent on the molecular proximity between the
energy donor, Renilla luciferase (Rluc), and acceptor, green
£uorescent protein (GFP), making it ideal for studying pro-
tein^protein interactions. The improved BRET technique
(BRET2) that o¡ers greatly improved separation of the emis-
sion spectra of the donor and acceptor moieties compared to
traditional BRET was employed in this study [7].
2. Materials and methods
2.1. cDNA constructs, cell culture and transfection
The cDNA construct of hemagglutinin (HA)-A1R-modi¢ed green
£uorescent protein (GFP2) and Myc-tagged P2Y1R (Myc-P2Y1R)-
Rluc were generated by ampli¢cation of the HA-tagged rat A1R
and Myc-tagged rat P2Y1R coding sequence [5] without its stop co-
don using sense and antisense primers containing distinct restriction
enzyme sites at the 5P and 3P ends, respectively. The fragments were
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Fig. 1. Double-£uorescence imaging of HA-A1R-GFP2 and Myc-P2Y1-Rluc in HEK293T cells. HEK293T cells transfected with HA-A1R-GFP2
(A^D) or Myc-P2Y1R-Rluc (E^H) were treated with 1 WM CPA (B,F), 100 WM ADPLS (C,G) or 1 WM CPA+100 WM ADPLS (D,H) for
10 min. Confocal laser microscopy was employed to visualize GFP2 (green images) and rhodamine (red images). Scale bar, 10 Wm. I^Q: Co-
localization of HA-A1R-GFP2 and Myc-P2Y1-Rluc in HEK293T cells. HA-A1R-GFP2/Myc-P2Y1R-Rluc co-transfected HEK293T cells were in-
cubated for 10 min with (L^N) or without (I^K) the agonists (1 WM CPA+100 WM ADPLS). HA-A1R-GFP2/Myc-D2LR co-expressing cells
were incubated for 10 min with the agonists (1 WM CPA+100 WM ADPLS, O^Q). They were visualized by double-£uorescence imaging with a
confocal laser microscope to detect GFP2 (I,L,O, green images) and rhodamine (J,M,P, red images). GFP2 and rhodamine images were merged
using confocal assistant software to reveal HA-A1R-GFP2/Myc-P2Y1R-Rluc co-localization (K,N,Q, yellow images). Scale bar, 10 Wm.
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then subcloned in-frame into the appropriate sites of the codon
humanized pGFP2-N3 and pRluc-N3 expression vectors (BRET2,
Packard Biosciences), respectively. Rluc and GFP2 were located at
the C-terminal end of the receptors.
HEK293T cells were maintained and were transfected transiently as
described previously [5]. Cells were harvested 48 h after transfection
and washed twice in ice-cold phosphate-bu¡ered saline (PBS) before
co-immunoprecipitation and BRET experiments.
2.2. Confocal laser microscopy and co-immunoprecipitation
Confocal microscopic observations were made with a Zeiss LSM410
confocal microscope. Co-transfected cells were labeled with rhoda-
mine-conjugated anti-Myc monoclonal antibody (1:200, Santa
Cruz). GFP2 and rhodamine were excited using a 488 nm and
543 nm argon/krypton laser and detected with a 510^525 nm band-
pass ¢lter and a 560 nm longpass ¢lter, respectively. The images were
manipulated with Zeiss LSM software. Co-immunoprecipitation stud-
ies were performed as described previously [5].
2.3. BRET2 assay
Approximately 5U105 cells per well suspended in the assay bu¡er
(Dulbecco’s PBS containing 0.1 g/l CaCl2, 0.1 g/l MgCl2 and 1 g/l
D-glucose) were distributed in a 96-well white-walled microplate
(Packard Biosciences). The cells were incubated with or without re-
ceptor ligands for speci¢c periods at 37‡C. The coelenterazine deriv-
ative DeepBlue C (Packard Biosciences), Rluc substrate, was added at
a ¢nal concentration of 5 WM and signal was detected immediately by
using a fusion microplate analyzer (Packard Biosciences) with 410 and
515 nm emission ¢lters. Background was taken as the area of this
region of the spectrum without transfectants. Data are represented
as a BRET ratio de¢ned as [(emission at 515 nm)3(background emis-
sion at 515 nm)]/[(emission at 410 nm)3(background emission at
410 nm)].
3. Results
3.1. Co-localization of A1R and P2Y1R and their
agonist-induced translocation in HEK293T cells
Localization of HA-tagged A1R (HA-A1R)-GFP2 in the
plasma membrane of HEK293T cells expressing HA-A1R
fused to GFP2 (HA-A1R-GFP2) alone is shown in Fig. 1A^
D. Addition of N6-cyclopentyladenosine (CPA) to the trans-
fected cells resulted in the appearance of intense punctate
areas of signal on the plasma membrane, suggesting a cluster-
ing of HA-A1R-GFP2 (Fig. 1B,D). Vehicle or CPA addition
showed a broad distribution of Myc-P2Y1R on the surface of
Myc-P2Y1R fused to Rluc (Myc-P2Y1R-Rluc)-transfected
HEK293T cells (Fig. 1E,F), whereas either adenosine 5P-O-
(2-thiotriphosphate) (ADPLS)- or combined-agonist-treated
cells revealed a structure where P2Y1R accumulated to plasma
membranes and a microspike-like structure was present on the
surface of cells (Fig. 1G,H).
A homogeneous co-localization of HA-A1R-GFP2 and
Myc-P2Y1R-Rluc on the plasma membrane was observed in
vehicle-treated (Fig. 1I^K) and also in CPA-treated cells (data
not shown). When cells were treated with CPA+ADPLS, a
redistribution and co-localization of these receptors were ob-
served (Fig. 1L^N). Clusters of HA-A1R-GFP2, seen as the
punctate accumulation of GFP2 signals as shown in Fig.
1B,D, disappeared and were translocated to the plasma mem-
brane (Fig. 1L). Microspikes were present on the cell surface
where co-localization between HA-A1R-GFP2 and Myc-
P2Y1R-Rluc was shown to be very intense (Fig. 1N, yellow).
These agonist-dependent translocation shown in Fig. 1L^N
was not observed in HA-A1R/Myc-D2LR-Rluc coexpressing
cells (Fig. 1O^Q), indicating that A1R and P2Y1R co-operate
together via the same tra⁄cking pathway.
3.2. Association of HA-A1R-GFP2 and Myc-P2Y1R-Rluc in
HEK293T cells assessed by co-immunoprecipitation
Western blots of cell membrane lysates expressing Myc-
P2Y1R-Rluc exhibited anti-Myc reactive bands of 76 and 84
kDa near the predicted molecular mass in addition to bands
of 160 and s 250 kDa (Fig. 2A, lanes 3,4). Western blots of
cell membrane lysates expressing HA-A1R-GFP2 showed anti-
HA antibody reactive bands of 59 and 66 kDa in addition to
bands of a potential dimer and oligomer (Fig. 2B, lanes 2,4).
We found that anti-Myc antibody co-immunoprecipitated
HA-A1R-GFP2 (Fig. 2B, lane 8) in addition to Myc-P2Y1R-
Rluc (Fig. 2A, lane 8) from cells co-expressing HA-A1R-
GFP2/Myc-P2Y1R-Rluc. Conversely, anti-HA antibody im-
munoprecipitated HA-A1R-GFP2 with Myc-P2Y1R-Rluc
(data not shown). These results indicate that constitutive het-
ero-oligomerization between A1R and P2Y1R can occur not
only with HA-A1R and Myc-P2Y1R tagged with short pep-
tides [5] but also between HA-A1R-GFP2 and Myc-P2Y1R-
Rluc when expressed as fusion proteins.
3.3. Association of HA-A1R-GFP2 and Myc-P2Y1R-Rluc in
HEK293T cells assessed by BRET2
To determine whether there is a constitutive association
between A1R/A1R or A1R/P2Y1R in living cells, BRET2
was measured in HEK293T cells co-transfected with either
HA-A1R-GFP2/HA-A1R fused to Rluc (HA-A1R-Rluc) or
Fig. 2. Co-immunoprecipitation of HA-A1R-GFP2 and Myc-
P2Y1R-Rluc expressed in HEK293T cells. Cell lysates were immu-
noprecipitated with anti-Myc antibodies, and samples resolved by
SDS^PAGE and immunoblotted with anti-Myc (A, right panel) or
anti-HA (B, right panel) antibodies. Cell lysates (left panels of A,
B) were prepared from HKE293T cells transiently expressing the in-
dicated receptors. Myc-P2Y1R-Rluc (upper column, lanes 3, 4) and
HA-A1R-GFP2 (lower column, lanes 2, 4) were detected by anti-
Myc and anti-HA antibodies, respectively. In addition to Myc-
P2Y1R-Rluc (A, lanes 7, 8), anti-Myc antibodies immunoprecipi-
tated HA-A1R-GFP2 from cell membrane lysates co-expressing HA-
A1R-GFP2/Myc-P2Y1R-Rluc (B, lane 8). Data are representative of
four independent experiments.
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HA-A1R-GFP2/Myc-P2Y1R-Rluc. As shown in Fig. 3A, co-
expression of HA-A1R-GFP2/HA-A1R-Rluc (BRET ra-
tio = 0.062V 0.004, n=15) or HA-A1R-GFP2/Myc-P2Y1R-
Rluc (BRET ratio= 0.07V 0.008, n=20) upon addition of
Rluc substrates resulted in a small but signi¢cant increase in
the BRET ratio (P6 0.05 versus control cells) under basal
conditions. Co-expression of the isolated Rluc along with
HA-A1R-GFP2 resulted in a weak energy transfer (BRET
ratio= 0.045V 0.005, n=6), indicating that there was no direct
interaction between these two constructs (Fig. 3A, lower line).
Similarly, co-expression of isolated GFP2 with Myc-P2Y1R-
Rluc failed to produce a signi¢cant energy transfer signal
(BRET ratio= 0.048V 0.006, n=6; data not shown). These
results provide strong evidence of an actual association be-
tween either A1R-GFP2 and A1R-Rluc or A1R-GFP2 and
P2Y1R-Rluc in intact cells. The extent of the heteromeric
association is substantially greater than that of the homomeric
association of A1R (P6 0.05). Incubation of HA-A1R-GFP2/
Myc-P2Y1R-Rluc-co-transfected cells with the agonists CPA
and ADPLS increased the BRET ratio with a maximum being
reached at 10 min (Fig. 3A, upper line). The agonist-promoted
BRET signal observed between HA-A1R-GFP2 and Myc-
P2Y1R-Rluc did not result from non-speci¢c association be-
tween the GFP2 and Rluc proteins since no increase in the
signal intensity was detected in cells expressing either HA-
A1R-GFP2/Rluc or HA-A1R-GFP2/HA-A1R-Rluc as shown
above. It was also con¢rmed that the BRET signal did not
strengthen in cells co-expressing GFP2 and Rluc (0.045V
0.008, n=6). Incubation of HA-A1R-GFP2/HA-A1R-Rluc
expressing cells with agonists did not result in a signi¢cant
increase in the BRET signal (Fig. 3A, middle line).
To demonstrate the speci¢city of the agonist-dependent in-
crease in the BRET ratio, HA-A1R-GFP2/Myc-P2Y1R-Rluc-
transfected cells were incubated for 10 min in the presence of
several ligands (Fig. 3B). A signi¢cant increase in the ratio
was again observed in the presence of both agonists, but not
with either alone. This increase was signi¢cantly inhibited by
pretreatment with N6-methyl-2P-deoxyadenosine-3P,5P-bis-
phosphate (MRS2179), a potent P2Y1R antagonist, although
the addition of MRS2179 alone had no e¡ect on the BRET
ratio. We then examined whether the increase in heteromeric
formation between HA-A1R-GFP2 and Myc-P2Y1R-Rluc in-
duced by the agonists was also detectable in immunoprecipi-
tation experiments. No signi¢cant increase in the amount of
bound counter receptor proteins was observed (data not
shown). It is possible that the agonist-dependent oligomeriza-
tion might be weak association which could not be detected
by the co-immunoprecipitation technique employed in this
study, although it remains to be further examined to address
this speculation.
4. Discussion
There has been an increasing number of reports describing
the existence and functional importance of homo- and hetero-
oligomerization of GPCRs (see review [4]). However, the
mechanism of the oligomerization is still largely unknown,
and it is not clear whether such oligomers persist at the cell
membranes and whether the binding of agonist ligands regu-
lates oligomerization. To answer these questions, co-immuno-
precipitation strategies seem limited because the solubilization
of hydrophobic proteins such as GPCRs can cause artifactual
aggregations or the solubilization process itself can inhibit the
association between GPCRs.
In this study, we ¢rst performed a confocal microscopy to
observe the co-localization of A1R and P2Y1R in HEK293T
cells and then utilized a biophysical method, BRET2, to dem-
onstrate that A1R and P2Y1R can undergo agonist-dependent
hetero-oligomerization in living cells.
The cluster formation of HA-A1R-GFP2 by A1R agonist,
CPA, was attenuated by co-transfection with Myc-P2Y1R-
Rluc (Fig. 1L), suggesting a mechanism by which P2Y1R
negatively regulates the ligand-induced clustering of A1R.
Saura et al. [8] recently reported that the cluster formation
of A1R was accelerated by the presence of either an A1R
agonist or by adenosine deaminase treatment. The distribu-
Fig. 3. BRET2 detection of HA-A1R-GFP2 and Myc-P2Y1R-Rluc
in living cells. A: Time-dependent BRET signal in living HEK293T
cells co-expressing HA-A1R-GFP2 and HA-A1R-Rluc (homo-oligo-
mer, triangle), HA-A1R-GFP2 and Myc-P2Y1R-Rluc (hetero-oligo-
mer, circle) or HA-A1R-GFP2 and Rluc (control, square). Cells
were incubated with agonists of A1R and P2Y1R (1 WM CPA+100
WM ADPLS) before the addition of Rluc substrates. The data
shown represent the meanVS.E.M. of three independent experi-
ments performed in triplicate for each time point. B: BRET ratio
was measured in HEK293T cells co-transfected with HA-A1R-GFP2
and Myc-P2Y1R-Rluc. Cells were incubated with either CPA
(1 WM), ADPLS (100 WM), P2Y1R antagonist MRS2179 (1 mM) or
a combination thereof for 10 min before the addition of Rluc sub-
strate. The data represent the meanVS.E.M. of three independent
experiments, **P6 0.01 compared with vehicle treatment (control),
*P6 0.05 compared with CPA and ADPLS treatment (GraphPad
Prism 3).
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tion of Myc-P2Y1R-Rluc was signi¢cantly altered by the ad-
dition of the P2Y1R agonist, ADPLS. The translocated Myc-
P2Y1R-Rluc appeared in both plasma membranes and micro-
spike-like structures on the cell surface (Fig. 1G,H). Although
co-localization of HA-A1R-GFP2 with Myc-P2Y1R-Rluc was
demonstrated regardless of the receptor activation (Fig.
1K,N), it was clearly demonstrated that these receptors co-
localized in the microspike-like structures in the presence of
ADPLS (Fig. 1N). It should also be noted that P2Y1R is
involved in ADP-induced platelet shape change [9].
Direct interaction between HA-A1R-GFP2 and Myc-
P2Y1R-Rluc in intact cells was observed by a BRET2 tech-
nique that o¡ers greatly improved separation of the emission
spectra of the donor and acceptor moieties compared to tradi-
tional BRET [7,10]. It should be noted that even small BRET
ratio can be determined quantitatively with this system due to
its low background. As shown in Fig. 3, receptor stimulation
led to a time-dependent increase in the amount of energy
transfer in cells co-expressing HA-A1R-GFP2/Myc-P2Y1R-
Rluc in addition to energy transfer in a constitutive associa-
tion between these receptors. Interestingly, such a ligand-de-
pendent promotion of BRET2 signaling requires agonists for
both receptors (Fig. 3B). The e¡ect of the agonists on the
BRET ratio is consistent with the notion that agonists pro-
mote the formation of hetero-oligomers [11]. Because ADPLS
is a hydrophilic ligand that cannot permeate the plasma mem-
brane, the results indicate that the heteromeric assembly of
receptors occurs at the cell surface, in£uenced by speci¢c re-
ceptor activation. A signi¢cant inhibition with the P2Y1R
selective antagonist MRS2179 suggests that receptor activa-
tion is indeed involved in this agonist-promoted oligomeriza-
tion (Fig. 3B). Our results also revealed that the A1R homo-
oligomer is present in living HEK293T cells co-expressing
A1R-GFP2 and A1R-Rluc, although this homodimer forma-
tion seems to be agonist-independent. The presence of homo-
dimer between A1R has also been suggested by Western blot
experiments (Fig. 2B and [12]). Human L2-adrenergic recep-
tors are similarly reported to form constitutive and agonist-
dependent homodimers when expressed in HEK293 cells as
determined by traditional BRET [13]. In contrast, using a
similar BRET technique, it was found that the human N-opioid
receptor forms homo-oligomers constitutively that were not
further regulated by ligand occupancy [11].
It has been shown in immunoprecipitation experiments that
A1R/dopamine D1 receptor hetero-oligomerization in co-
transfected ¢broblast cells disappeared on pretreatment with
D1 receptor agonist but not combined pretreatment with
D1 receptor and A1R agonists [14]. McVey et al. [11] have
reported that the hetero-oligomer of N-opioid receptor and
L2-adrenoreceptor accumulated in the presence of an agonist
for either receptor. These observations suggest that the role of
agonist occupancy of receptors in homo- or hetero-oligomeri-
zation of GPCRs can di¡er between receptors. The present
result in the BRET2 experiment that combined agonists fur-
ther promoted hetero-oligomerization of two purinergic recep-
tors may support this observation. It remains to be deter-
mined whether such agonist-dependent changes in the
heteromeric association of A1R and P2Y1R constitute impor-
tant physiological roles in the nervous system where both
receptors are highly expressed. The diversity of purinergic
functions may indicate a greater number of purinergic recep-
tor subtypes than has been revealed in cloning studies [15^19].
The heteromerization described here may be one of the mech-
anisms that control such purinergic functions.
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